A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

Table 3 Mean change in hemoglobin level from baseline to end of cycle 4

Hemoglobin (g/dL)	10 mg/kg without oral iron (cohort B1) (n = 6)	10 mg/kg with oral iron (cohort B2) (n = 7)	Total (n = 13)
Baseline^a
Mean (SD)	9.8 (0.71)	9.5 (0.31)	9.6 (0.53)
Range	8.8, 10.8	9.0, 9.9	8.8, 10.8
Change from baseline to end of cycle 4
Mean (SD)	−0.5 (0.49)	−0.2 (0.80)	−0.4 (0.65)
60% CI for mean^b	−0.69, −0.31	−0.53, 0.07	−0.53, −0.20

Values shown are for the evaluable population (i.e., patients in study part B who received all four of the first four per-cycle doses of LY2787106)
CI confidence interval, SD standard deviation
^aBaseline is defined as the last reported measure before first dose
^bConfidence intervals are based on the t distribution. Each side of a 2-sided 60% CI is the same as a 1-sided 80% confidence limit

ISSN: 1756-8722